<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675181</url>
  </required_header>
  <id_info>
    <org_study_id>087-KRK-2008-002</org_study_id>
    <nct_id>NCT00675181</nct_id>
  </id_info>
  <brief_title>Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow</brief_title>
  <acronym>MelO2</acronym>
  <official_title>Effects of Melatonin on Oxygen Consumption and Choroidal Blood Flow in Women With Vasospastic Syndrome in Comparison to Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Does melatonin affect basal metabolic rate, increase choroidal blood flow and reduce the
      vasospastic syndrome (VS)?

      The main questions are:

      Do women with VS exhibit...

        -  a different basal metabolic rate

        -  a reduced choroidal blood flow

        -  a reduced increase of oxygen consumption after intake of ice-water

        -  a different oxygen consumption after melatonin intake

        -  a different choroidal blood flow after melatonin intake

        -  a different oxygen consumption after melatonin intake and after intake of ice-waterâ€¦.?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study description:

      Melatonin, a natural hormone of the pineal gland exclusively released during the dark phase,
      exhibits vasodilatatory effects in distal skin regions and reduces core body temperature.
      This study investigates whether exogenous melatonin (5mg p.o. at 2p.m.) in the afternoon,
      when no endogenous melatonin is secreted, increases not only distal skin blood flow, but also
      choroidal blood flow and changes oxygen consumption. Two subject groups were studied, women
      with vasospastic syndrome (VS) and controls. The main hypothesis is: melatonin normalizes
      distal vasoconstriction in VS.

      Further questions will also be answered:

      Does melatonin affect basal metabolic rate, increase choroidal blood flow and reduce the
      vasospastic syndrome (VS)?

      Do women with VS exhibit:

        -  a different basal metabolic rate

        -  a reduced choroidal blood flow

        -  a reduced increase of oxygen consumption after intake of ice-water

        -  a different oxygen consumption after melatonin intake

        -  a different choroidal blood flow after melatonin intake

        -  a different oxygen consumption after melatonin intake and after intake of ice-water....?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-choroidal blood flow -oxygen consumption -Co2 production -skin temperatures -rectal temperatures -blood pressure -eye tension</measure>
    <time_frame>continously or 2-5 times</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Vasospastic Syndrome</condition>
  <arm_group>
    <arm_group_label>A, 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A, 1 = Melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A,2 = Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>5mg per os</description>
    <arm_group_label>A, 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>per os</description>
    <arm_group_label>A, 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  vasospastic syndrome

          -  healthy

        Exclusion Criteria:

          -  sick

          -  BMI &gt;25 or &lt;18

          -  migraine

          -  drug intake
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selim Orguel, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Eye Clinic, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Eye Clinic</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>skin blood flow</keyword>
  <keyword>choroidal blood flow</keyword>
  <keyword>vasospastic subjects</keyword>
  <keyword>normal subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

